Volociximab
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | α5β1 integrin |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6434H9942N1706O2040S52 |
| Molar mass | 145501.33 g·mol−1 |
  (what is this?) (verify) | |
It is thought to reduce metastases. Early results show potential in renal cell cancers.
References
- Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW (January 2010). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients". Cancer Chemotherapy and Pharmacology. 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731. S2CID 23035675.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.